YB Urban Renewal Residential Development Ltd, formerly known as Cannassure Therapeutics Ltd, is an Israel-based urban renewal company. The Company is engaged mainly in urban renewal projects. In the urban renewal projects sector, the Company partakes in activities that aim to clear out areas of inner cities deemed to be neglected, unused and loosely maintained, in favor of new multifamily housing, business areas, as well as other developments improving the city landscape. The Firm aims to achieve economic, cultural and environmental renewal of the neglected inner city areas. The Company cooperates with a range of specialists in the field of urban renewal with knowledge and experience in urban planning and construction work.

Employees

Sector

Real Estate Development & Operations

More about the company

Market Cap	28.92M 9.61M 8.27M 7.78M 7.1M 13.29M 907M 13.33M 91.9M 35.66M 465M 36.07M 35.28M 1.5B	P/E 2024	-4.93x	P/E 2025	-9.22x
Enterprise Value	29.03M 9.64M 8.3M 7.81M 7.13M 13.34M 911M 13.38M 92.26M 35.8M 467M 36.21M 35.42M 1.51B	EV / Sales 2024	376x	EV / Sales 2025	-
Free-Float	54.18%	Yield 2024 *	-	Yield 2025	-

Aug. 30	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Half Year Ended June 30, 2026	CI
May. 03	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
May. 02	Y.B Urban Renewal - Residential Development Ltd Auditor Raises 'Going Concern' Doubt	CI
Nov. 12	Y.B Urban Renewal - Residential Development Ltd announced that it expects to receive ILS 0.53001 million in funding	CI
25-09-10	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
24-09-01	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-07-11	Cannassure Therapeutics Ltd will Change its Name to Y.B URBAN RENEWAL - RESIDENTIAL DEVELOPMENT LTD	CI
24-03-27	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-03-26	Y.B Urban Renewal - Residential Development Ltd Auditor Raises 'Going Concern' Doubt	CI
23-08-31	Cannassure Therapeutics Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	CI
23-03-26	Cannassure Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	CI
21-08-09	Cannassure Was Granted A Patent for an Oral Delivery Method of Cannabis and Cannabinoids Compositions by the Israel Patents Authority	CI

21-02-26	DanCann Pharma A/S : publishes Year-end report for 2020	AQ
21-01-18	Cannassure Therapeutics : DanCann Pharma's strategic partner, Cannassure Therapeutics Ltd., enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO® technology	AQ
21-01-18	Lipidor : and Cannassure enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO technology	AQ
20-12-15	DanCann Pharma A/S : enter exclusive agreement with Cannassure Therapeutics to be multinational distributor for Scandinavia (Denmark, Norway, Sweden, and Finland)	AQ
20-11-19	Lipidor : publishes interim report for Q3 2020	AQ

Manager	Title	Age	Since
Ada Bar Kama CEO	Chief Executive Officer	56	2022-03-30
Oren Attiya DFI	Director of Finance/CFO	45	-
Daniel Shapira AUD	Comptroller/Controller/Auditor	72	2019-06-25

Director	Title	Age	Since
Nir Peles CHM	Chairman	53	2021-12-08
Shimon Bar-Kama BRD	Director/Board Member	74	2018-12-03
Varda Kalal BRD	Director/Board Member	58	2022-02-13

Cannassure Therapeutics Ltd Stock TEL AVIV STOCK EXCHANGE

Stocks

CSURE

IL0001110134

Real Estate Development & Operations

Valuation : Cannassure Therapeutics Ltd

Latest news : Cannassure Therapeutics Ltd

Press Releases : Cannassure Therapeutics Ltd

Quotes and Performance

Managers and Directors : Cannassure Therapeutics Ltd

Other Real Estate Development & Operations

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CANNASSURE THERAPEUTICS LTD	-7.54%	-22.20%	-	-	9.61M
SUN HUNG KAI PROPERTIES LIMITED	+3.64%	-1.97%	+30.74%	+32.12%	44.16B
MITSUBISHI ESTATE CO., LTD.	-0.27%	-3.50%	+15.41%	+90.66%	28.47B
CHINA RESOURCES LAND LIMITED	+0.13%	-8.08%	-0.72%	-16.32%	27.74B
MITSUI FUDOSAN CO., LTD.	-0.33%	-1.95%	-4.76%	+35.71%	26.04B
EMAAR PROPERTIES	+2.23%	0.00%	-23.34%	+54.28%	26.47B
CK ASSET HOLDINGS LIMITED	+2.11%	+3.23%	+29.27%	+10.22%	21.13B
ALPHA DHABI HOLDING	+0.41%	-4.30%	-32.04%	-63.26%	19.97B
SUMITOMO REALTY & DEVELOPMENT CO., LTD.	-0.55%	-4.65%	+4.99%	+63.91%	19.16B
CHINA OVERSEAS LAND & INVESTMENT LIMITED	0.00%	-4.70%	-3.87%	-26.51%	18.38B
Average	-0.02%	-2.90%	+1.74%	+20.09%	25.73B
Weighted average by Cap.	+1.08%	-2.85%	+4.48%	+24.20%

	2024	2025
Net sales	76K 25.24K 21.72K 20.44K 18.67K 34.93K 2.38M 35.02K 242K 93.72K 1.22M 94.8K 92.73K 3.94M	-
Net income	-3.68M -1.22M -1.05M -988K -903K -1.69M -115M -1.69M -11.68M -4.53M -59.13M -4.58M -4.48M -191M	-3M -995K -856K -806K -736K -1.38M -93.96M -1.38M -9.52M -3.69M -48.21M -3.74M -3.66M -155M
Net Debt	980K 326K 280K 264K 241K 450K 30.73M 452K 3.11M 1.21M 15.77M 1.22M 1.2M 50.8M	115K 38.2K 32.87K 30.93K 28.25K 52.85K 3.61M 52.99K 365K 142K 1.85M 143K 140K 5.96M